PLRZ

Polyrizon Ltd.

Price Chart

Latest Quote

$13.20

-0.22 (-1.63%)

Current Price

Previous Close	$13.42
Open	$13.19
Day High	$13.39
Day Low	$12.99
Volume	7,314

Fetched: 2026-06-22T14:55:31

Stock Information

Shares Outstanding	2.08M
Cash Equivalents	$12.27M
Net Income	$-3.33M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$27.51M
EPS (TTM)	$-4.90
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$9.50M
Income	$-3.33M
Book/sh	$13.05
Cash/sh	$5.89
Employees	2

Financial Ratios

Quick Ratio	27.70
Current Ratio	29.03

Returns & Margins

ROA	-28.95%
ROE	-25.38%

Ownership

Insider Ownership	0.83%
Institutional Ownership	8.31%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

1.01

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$13.51
SMA50	$13.84
SMA200	$10.86
RSI	37.46
ATR	1.5501

Shares Float	1.42M
Short Float	1.65%
Short Ratio	0.76
Rel Volume	0.19

Performance History

Week	+18.60%
Month	-2.58%
Quarter	-3.65%
6 Months	+29.92%
YTD	+3.53%
Year	+190.24%
10 Years	-99.43%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-22	$13.20	7,314
2026-06-18	$13.42	66,700
2026-06-17	$13.23	95,500
2026-06-16	$11.45	81,600
2026-06-15	$10.83	25,100
2026-06-12	$11.13	27,400
2026-06-11	$11.58	34,400
2026-06-10	$11.06	37,300
2026-06-09	$11.45	5,800
2026-06-08	$12.52	14,600
2026-06-05	$12.99	48,200
2026-06-04	$12.80	26,400
2026-06-03	$13.46	18,400
2026-06-02	$14.09	30,800
2026-06-01	$15.41	18,300
2026-05-29	$17.17	35,700
2026-05-28	$16.50	76,000
2026-05-27	$16.49	41,800
2026-05-26	$16.07	36,600
2026-05-22	$15.26	47,000

About Polyrizon Ltd.

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

📰 Latest News

This Former Penny Stock Just Doubled for the Second Time This Week. Should You Chase the Rally Here?

Barchart • 2025-12-05T15:26:33Z

We Think Polyrizon (NASDAQ:PLRZ) Can Afford To Drive Business Growth

Simply Wall St. • 2025-12-05T11:01:08Z

BC-Most Active Stocks

Associated Press Finance • 2025-12-02T15:30:17Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$5,785,000	$1,302,000	$635,000	$895,000
Other Income Expense	$5,223,000	$-215,000	$265,000	$92,000
Net Non Operating Interest Income Expense	$-2,773,000	$-28,000	$-230,000	$24,000
Total Other Finance Cost	$3,143,000	$28,000	$230,000	$-24,000
Operating Expense	$5,785,000	$1,302,000	$635,000	$895,000
General And Administrative Expense	$3,652,000	$768,000	$303,000	$533,000
Selling And Marketing Expense	-	$0	$0	$15,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-3,335,000	$-1,545,000	$-600,000	$-779,000
Net Interest Income	$-2,773,000	$-28,000	$-230,000	$24,000
Interest Income	$370,000	$0	$0	-
Normalized Income	$-8,558,000	$-1,330,000	$-865,000	$-871,000
Net Income From Continuing And Discontinued Operation	$-3,335,000	$-1,545,000	$-600,000	$-779,000
Total Operating Income As Reported	$-6,249,000	$-1,302,000	$-635,000	$-895,000
Net Income Common Stockholders	$-3,335,000	$-1,605,000	$-669,000	$-823,000
Net Income	$-3,335,000	$-1,545,000	$-600,000	$-779,000
Net Income Including Noncontrolling Interests	$-3,335,000	$-1,545,000	$-600,000	$-779,000
Net Income Continuous Operations	$-3,335,000	$-1,545,000	$-600,000	$-779,000
Pretax Income	$-3,335,000	$-1,545,000	$-600,000	$-779,000
Special Income Charges	$-464,000	-	-	-
Interest Income Non Operating	$370,000	$0	$0	-
Operating Income	$-5,785,000	$-1,302,000	$-635,000	$-895,000
Per Share
Diluted EPS	-	$-805.20	$-239.27	$-294.35
Basic EPS	-	$-805.20	$-239.27	$-294.35
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-10,666,000	$-969,000	$-896,000	$-982,000
Total Unusual Items	$5,223,000	$-215,000	$265,000	$92,000
Total Unusual Items Excluding Goodwill	$5,223,000	$-215,000	$265,000	$92,000
Reconciled Depreciation	$342,000	$118,000	$4,000	$5,000
EBITDA (Bullshit earnings)	$-5,443,000	$-1,184,000	$-631,000	$-890,000
EBIT	$-5,785,000	$-1,302,000	$-635,000	$-895,000
Diluted NI Availto Com Stockholders	$-3,335,000	$-1,605,000	$-669,000	$-823,000
Other Special Charges	$464,000	-	-	-
Gain On Sale Of Security	$5,687,000	$-215,000	$265,000	$92,000
Research And Development	$2,133,000	$534,000	$332,000	$347,000
Selling General And Administration	$3,652,000	$768,000	$303,000	$548,000
Other Gand A	$2,524,000	$606,000	$135,000	$343,000
Salaries And Wages	$1,128,000	$162,000	$168,000	$190,000
Diluted Average Shares	-	$1,994	$2,796	$2,796
Basic Average Shares	-	$1,994	$2,796	$2,796
Preferred Stock Dividends	-	$60,000	$69,000	$44,000

Fetched: 2026-06-18

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$18,447,000	$2,402,000	$-191,000	$-900,000
Total Assets	$21,437,000	$5,547,000	$559,000	$546,000
Total Non Current Assets	$8,577,000	$2,894,000	$505,000	$495,000
Non Current Prepaid Assets	$6,018,000	$0	-	-
Goodwill And Other Intangible Assets	$2,547,000	$2,884,000	$0	-
Current Assets	$12,860,000	$2,653,000	$54,000	$51,000
Other Current Assets	$396,000	$99,000	$13,000	$15,000
Cash Cash Equivalents And Short Term Investments	$12,464,000	$2,554,000	$41,000	$36,000
Cash And Cash Equivalents	$1,306,000	$2,554,000	$4,000	$36,000
Non Current Deferred Assets	-	$0	$493,000	$479,000
Debt
Net Debt	-	-	$196,000	$586,000
Total Debt	-	-	$200,000	$622,000
Current Debt And Capital Lease Obligation	-	-	$200,000	$622,000
Current Debt	-	-	$200,000	$622,000
Other Current Borrowings	-	-	$200,000	$622,000
Liabilities
Total Liabilities Net Minority Interest	$443,000	$261,000	$750,000	$1,446,000
Total Non Current Liabilities Net Minority Interest	$0	$0	$248,000	$248,000
Current Liabilities	$443,000	$261,000	$502,000	$1,198,000
Payables And Accrued Expenses	$294,000	$216,000	$158,000	$141,000
Other Current Liabilities	-	-	$105,000	$398,000
Equity
Common Stock Equity	$20,994,000	$5,286,000	$-191,000	$-900,000
Total Equity Gross Minority Interest	$20,994,000	$5,286,000	$-191,000	$-900,000
Stockholders Equity	$20,994,000	$5,286,000	$-191,000	$-900,000
Retained Earnings	$-8,401,000	$-5,066,000	$-3,521,000	$-2,921,000
Preferred Securities Outside Stock Equity	-	$0	$248,000	$248,000
Other Equity Interest	-	-	$-196,000	-
Other
Ordinary Shares Number	$1,608,266	$2,796	$2,796	$2,796
Share Issued	$1,608,266	$2,796	$2,796	$2,796
Tangible Book Value	$18,447,000	$2,402,000	$-191,000	$-900,000
Invested Capital	$20,994,000	$5,286,000	$9,000	$-278,000
Working Capital	$12,417,000	$2,392,000	$-448,000	$-1,147,000
Total Capitalization	$20,994,000	$5,286,000	$-191,000	$-900,000
Additional Paid In Capital	$29,395,000	$10,352,000	$3,526,000	$2,021,000
Capital Stock	$0	$0	$0	$0
Common Stock	$0	$0	$0	$0
Pensionand Other Post Retirement Benefit Plans Current	$149,000	$45,000	$39,000	$37,000
Current Accrued Expenses	$294,000	$216,000	$158,000	$141,000
Net PPE	$12,000	$10,000	$12,000	$16,000
Other Short Term Investments	$11,158,000	$0	$37,000	$0

Fetched: 2026-06-18

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-4,535,000	$-1,147,000	$-537,000	$-1,135,000
Operating Activities
Operating Cash Flow	$-4,528,000	$-1,147,000	$-537,000	$-1,132,000
Cash Flow From Continuing Operating Activities	$-4,528,000	$-1,147,000	$-537,000	$-1,132,000
Operating Gains Losses	$-5,144,000	$211,000	$-293,000	$-118,000
Investing Activities
Capital Expenditure	$-7,000	-	-	$-3,000
Investing Cash Flow	$-16,534,000	$29,000	$0	$-3,000
Cash Flow From Continuing Investing Activities	$-16,534,000	$29,000	$0	$-3,000
Financing Activities
Issuance Of Capital Stock	$19,814,000	$3,674,000	$256,000	$0
Financing Cash Flow	$19,814,000	$3,668,000	$505,000	$648,000
Cash Flow From Continuing Financing Activities	$19,814,000	$3,668,000	$505,000	$648,000
Net Common Stock Issuance	$19,814,000	$3,674,000	$256,000	$0
Common Stock Issuance	$19,814,000	$3,674,000	$256,000	$0
Other
Repayment Of Debt	$0	$-316,000	$0	$0
Issuance Of Debt	$0	$310,000	$249,000	$648,000
End Cash Position	$1,306,000	$2,554,000	$4,000	$36,000
Beginning Cash Position	$2,554,000	$4,000	$36,000	$523,000
Changes In Cash	$-1,248,000	$2,550,000	$-32,000	$-487,000
Net Issuance Payments Of Debt	$0	$-6,000	$249,000	$648,000
Net Short Term Debt Issuance	$0	$0	$249,000	$648,000
Short Term Debt Issuance	$0	$0	$249,000	$648,000
Net Long Term Debt Issuance	$0	$-6,000	$0	$0
Long Term Debt Payments	$0	$-316,000	$0	$0
Long Term Debt Issuance	$0	$310,000	$0	$0
Net Investment Purchase And Sale	$-16,527,000	$29,000	$0	$0
Sale Of Investment	$0	$29,000	$0	$0
Purchase Of Investment	$-16,527,000	$0	$0	-
Net PPE Purchase And Sale	$-7,000	$0	$0	$-3,000
Purchase Of PPE	$-7,000	$0	$0	$-3,000
Change In Working Capital	$-158,000	$-21,000	$7,000	$-344,000
Change In Other Working Capital	$104,000	$6,000	$-12,000	$-335,000
Change In Other Current Assets	$-297,000	$-85,000	$2,000	$6,000
Change In Payables And Accrued Expense	$35,000	$58,000	$17,000	$-15,000
Change In Accrued Expense	$35,000	$58,000	$17,000	$-15,000
Other Non Cash Items	$2,457,000	$31,000	$228,000	$-26,000
Stock Based Compensation	$1,310,000	$51,000	$100,000	$130,000
Unrealized Gain Loss On Investment Securities	$0	$8,000	$17,000	$0
Depreciation Amortization Depletion	$342,000	$118,000	$4,000	$5,000
Depreciation And Amortization	$342,000	$118,000	$4,000	$5,000
Gain Loss On Investment Securities	$-5,144,000	$211,000	$-293,000	$-118,000
Net Income From Continuing Operations	$-3,335,000	$-1,545,000	$-600,000	$-779,000
Depreciation	-	$118,000	$4,000	$5,000

Fetched: 2026-06-18